Everolimus Shows Limited Cognitive Benefit in Tuberous Sclerosis RCT
A randomized trial of everolimus for neuropsychological deficits in TSC found high responder rates in both drug and placebo arms, clouding interpretation.
Summary
The TRON trial tested whether everolimus, an mTOR inhibitor already used for tumors and epilepsy in tuberous sclerosis complex (TSC), could also improve memory and executive function. Thirty-eight adults with TSC and documented cognitive deficits were randomized to 24 weeks of everolimus or placebo. Surprisingly, 87% of the everolimus group and 75% of the placebo group met the definition of cognitive responders — an unexpectedly high placebo response rate that makes it impossible to draw firm conclusions about drug efficacy. The trial highlights critical methodological challenges in designing neuropsychological studies in rare neurogenetic conditions, including practice effects and how "response" is defined. Results will help researchers design better-powered, more rigorously controlled future trials of mTOR-targeted cognitive therapies in TSC and related conditions.
Detailed Summary
Tuberous sclerosis complex (TSC) is a rare genetic disorder caused by mutations in TSC1 or TSC2, leading to overactivation of the mTOR pathway. Beyond causing benign tumors and drug-resistant epilepsy, TSC frequently impairs memory and executive function, diminishing quality of life significantly. mTOR inhibitors like everolimus are already approved for TSC-related tumors and seizures, but whether they can also rescue cognitive deficits has remained an open question with major therapeutic implications.
The TRON trial was a multicenter, randomized, placebo-controlled study enrolling adults aged 16–60 with TSC and confirmed neuropsychological deficits across memory or executive function domains. Participants were randomized 2:1 to 24 weeks of everolimus or placebo, with cognitive assessments at baseline and weeks 4, 12, 24, and 36. The primary endpoint was the proportion of "responders" — those improving by at least one standard deviation in at least one cognitive variable.
The results confounded expectations. An impressive 87% of participants on everolimus were classified as responders, but so were 75% on placebo. Effect sizes for individual cognitive variables were small to medium (Cohen's d ranging from 0 to 0.465). Adverse events were common in the everolimus arm (88%) versus placebo (61.5%), consistent with the known safety profile of mTOR inhibitors.
The high and overlapping responder rates in both arms almost certainly reflect methodological artifacts: test familiarity and practice effects from repeated cognitive assessments, psychometric limitations of parallel test forms, and a response definition sensitive enough to capture noise. These findings do not rule out a genuine cognitive benefit of everolimus in TSC — they reveal that the trial was not designed to detect one cleanly.
For the longevity and brain-health community, this is a cautionary tale about the difficulty of demonstrating cognitive benefits of mTOR modulation in humans, even in a condition where the biological rationale is exceptionally strong. Future trials must incorporate adaptive designs, better-matched parallel forms, and more conservative response thresholds to answer this important question.
Key Findings
- 87% of everolimus participants and 75% of placebo participants met cognitive responder criteria — no significant difference.
- Effect sizes for individual cognitive variables were small to medium (Cohen's d 0–0.465).
- Adverse events occurred in 88% of everolimus participants vs. 61.5% on placebo.
- High placebo response rates likely reflect practice effects and methodological limitations in repeated neuropsychological testing.
- Trial results underscore the need for improved study designs to evaluate mTOR inhibition on cognition in TSC and related conditions.
Methodology
Multicenter, double-blind, randomized controlled trial (2:1 everolimus vs. placebo) in 38 adults with TSC and confirmed cognitive deficits, assessed at baseline and weeks 4, 12, 24, and 36 using three validated neuropsychological batteries. The primary endpoint was proportion of responders (≥1 SD improvement in ≥1 cognitive variable). Outcome analyses were per-protocol, including 23 everolimus and 12 placebo completers.
Study Limitations
The summary is based on the abstract only, as the full text is not open access. The trial was small (38 randomized; 35 analyzable) and likely underpowered. The unexpectedly high placebo response rate — attributed to practice effects, psychometric issues, and a permissive responder definition — renders the primary endpoint uninterpretable for detecting a drug effect. Partial Novartis funding introduces potential conflict of interest.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: